Cardiovasc Drugs Ther. 2026 Jan 17. doi: 10.1007/s10557-025-07830-x. Online ahead of print.
ABSTRACT
Heart failure (HF) is a progressive clinical syndrome characterized by structural and functional cardiac impairment, leading to reduced cardiac output, hemodynamic instability, and high morbidity and mortality. Emerging evidence highlights calcitonin gene-related peptide (CGRP) as a crucial regulator of cardiovascular homeostasis, owing to its potent vasodilatory, cardioprotective, anti-inflammatory, and antifibrotic properties. CGRP, predominantly synthesized by sensory neurons, maintains vascular tone, enhances myocardial perfusion, and counteracts maladaptive neurohormonal activation involving the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS). In early HF, elevated CGRP levels provide compensatory benefits by reducing afterload, preserving endothelial integrity, and mitigating ventricular remodeling. However, progressive disease stages are characterized by CGRP depletion, receptor downregulation, and impaired signaling, which diminish its protective effects and contribute to pathological fibrosis, hypertrophy, and disruption of the extracellular matrix. Therapeutic strategies targeting CGRP signaling, including peptide agonists, stable analogues such as SAX, gene-based therapies enhancing endogenous CGRP expression, receptor modulators, and TRPV1-induced release stimulators, show promising results in preclinical studies and early-phase clinical studies, demonstrating improved cardiac output, reduced infarct size, and preserved ventricular function. Patients with early-to-mid HF (NYHA I-III), HFpEF with endothelial dysfunction, and hypertension-or-ischemia-driven HF may particularly benefit from CGRP-directed therapies. Conversely, the widespread use of CGRP antagonists for migraine therapy necessitates careful cardiovascular safety evaluation, especially in HF populations. Ongoing clinical trials are exploring CGRP-based interventions are diagnostic biomarkers, personalized therapeutic agents, and disease-modifying treatments. This review consolidates current insights into the physiological and pathophysiological roles of CGRP in HF, evaluates therapeutic opportunities and safety concerns, and discusses future directions, including patient stratification, biomarker-guided precision medicine, and combination regimens. Targeting CGRP pathways holds significant promise for redefining cardiovascular management and improving outcomes in HF.
PMID:41546811 | DOI:10.1007/s10557-025-07830-x